Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for familial primary localized cutaneous amyloidosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE4, 1 NA. Research is primarily sponsored by academic and government institutions.
25 publications have been identified in PubMed for familial primary localized cutaneous amyloidosis. Research spans Case Report / Case Series (48%), Review / Meta-Analysis (24%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:50 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
48%
Research summaries | 6 | 24% |
Testing and diagnosis research | 2 | 8% |
Laboratory research | 2 | 8% |
Other research | 1 | 4% |
Clinical study results | 1 | 4% |
New treatment approaches | 1 | 4% |
Hirao H (2026). [PMID: 41740427](https://pubmed.ncbi.nlm.nih.gov/41740427/). *Bioorg Med Chem*. [Basic Science / Preclinical]
Liao X (2026). [PMID: 42180761](https://pubmed.ncbi.nlm.nih.gov/42180761/). *Front Med (Lausanne)*. [Case Report / Case Series]
Teng Y (2026). [PMID: 42029085](https://pubmed.ncbi.nlm.nih.gov/42029085/). *Int J Dermatol*. [Review / Meta-Analysis]
Hoegl J (2026). [PMID: 41614014](https://pubmed.ncbi.nlm.nih.gov/41614014/). *Clin Case Rep*. [Case Report / Case Series]
Tashjian M (2026). [PMID: 42220857](https://pubmed.ncbi.nlm.nih.gov/42220857/). *Cureus*. [Review / Meta-Analysis]
Kashani AN (2025). [PMID: 40765512](https://pubmed.ncbi.nlm.nih.gov/40765512/). *J Dermatol*. [Diagnostic / Biomarker]
Liu X (2025). [PMID: 40955599](https://pubmed.ncbi.nlm.nih.gov/40955599/). *FASEB J*. [Diagnostic / Biomarker]
Garrigue A (2025). [PMID: 39847438](https://pubmed.ncbi.nlm.nih.gov/39847438/). *J Clin Invest*. [Case Report / Case Series]
Ishikawa C (2025). [PMID: 40677708](https://pubmed.ncbi.nlm.nih.gov/40677708/). *Front Immunol*. [Basic Science / Preclinical]
Wang QX (2025). [PMID: 39957318](https://pubmed.ncbi.nlm.nih.gov/39957318/). *Clin Exp Dermatol*. [Review / Meta-Analysis]
AI-curated news mentioning familial primary localized cutaneous amyloidosis
Updated Apr 24, 2026
A narrative review explores the roles of OSM and IL-31 in primary localized cutaneous amyloidosis, providing mechanistic insights that could inform future research and therapeutic strategies. This study contributes to the understanding of the disease's underlying biology.